Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Chief Operating Officer | May 30, 2017 | June 01, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Operating Officer | September 08, 2026 | September 10, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Chief Business Officer | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date May 30, 2017 · Filed June 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2027-05-29 | Direct | 87,161 |
Reported balance
After 2017-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-30 · Grant · Acquired 87,161 · Balance 87,161 F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,050 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 7,813 · Balance 146,050 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 142,074 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 3,976 · Balance 142,074 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,878 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 7,813 · Balance 46,878 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Oncternal Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.05 · Expires 2031-02-11 | Direct | 130,000 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 130,000 · Balance 130,000 F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2017 Filed Jun 1, 2017 23:49 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 87,161 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-17-036961 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,161 Underlying: Common Stock · 87,161 shares Expires 2027-05-29 F1 · derivative.exercise_date: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:36 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 176,411 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001209191-17-025164 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,411 Underlying: Common Stock · 176,411 shares Expires 2021-03-31 F1 · derivative.exercise_date: The shares subject to the option are 100% vested and exercisable as of the date of grant. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 20:06 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 247,322 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-17-006329 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,322 Underlying: Common Stock · 247,322 shares Expires 2027-01-29 F1 · derivative.exercise_date: 1/4th of the shares subject to the option vest on January 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.